Business Description
Balaxi Pharmaceuticals Ltd
ISIN : INE618N01022
Total Employee Number:
48Compare
Compare
Traded in other countries / regions
BALAXI.India IPO Date
2015-11-30Description
Balaxi Pharmaceuticals Ltd is an Indian branded IPR-based pharmaceutical company focusing on frontier markets, with a vast and growing portfolio of prescription and OTC drugs, across multiple therapeutic segments. The company operates in single segment Specialized Wholesale. Geographically it earns key revenue from Guatemala.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.25 | |||||
Equity-to-Asset | 0.74 | |||||
Debt-to-Equity | 0.23 | |||||
Debt-to-EBITDA | 5.08 | |||||
Interest Coverage | 1.63 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 2.48 | |||||
Beneish M-Score | -2.24 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -9.3 | |||||
3-Year EBITDA Growth Rate | -43.7 | |||||
3-Year EPS without NRI Growth Rate | -69.4 | |||||
3-Year FCF Growth Rate | -70.3 | |||||
3-Year Book Growth Rate | 8.4 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 56.6 | |||||
9-Day RSI | 53.39 | |||||
14-Day RSI | 50.41 | |||||
3-1 Month Momentum % | -5.54 | |||||
6-1 Month Momentum % | -11.5 | |||||
12-1 Month Momentum % | -53.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.05 | |||||
Quick Ratio | 2.7 | |||||
Cash Ratio | 0.23 | |||||
Days Inventory | 193.61 | |||||
Days Sales Outstanding | 160.38 | |||||
Days Payable | 45.91 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.3 | |||||
Shareholder Yield % | -10.73 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 44.16 | |||||
Operating Margin % | 2.36 | |||||
Net Margin % | 0.52 | |||||
EBITDA Margin % | 4.2 | |||||
FCF Margin % | -17.53 | |||||
OCF Margin % | -1.67 | |||||
ROE % | 0.59 | |||||
ROA % | 0.44 | |||||
ROIC % | 0.63 | |||||
3-Year ROIIC % | -34.24 | |||||
ROC (Joel Greenblatt) % | 4.01 | |||||
ROCE % | 3.48 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 92.46 | |||||
PE Ratio without NRI | 92.46 | |||||
Shiller PE Ratio | 6.54 | |||||
PS Ratio | 0.48 | |||||
PB Ratio | 0.54 | |||||
Price-to-Tangible-Book | 0.62 | |||||
EV-to-EBIT | 19.11 | |||||
EV-to-EBITDA | 15.49 | |||||
EV-to-Revenue | 0.65 | |||||
EV-to-FCF | -3.73 | |||||
Price-to-GF-Value | 0.35 | |||||
Price-to-Graham-Number | 1.6 | |||||
| Price-to-Net-Current-Asset-Value | 0.82 | |||||
Earnings Yield (Greenblatt) % | 5.23 | |||||
FCF Yield % | -35.68 | |||||
Forward Rate of Return (Yacktman) % | -41.1 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Balaxi Pharmaceuticals Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 2,701.735 | ||
| EPS (TTM) (₹) | 0.26 | ||
| Beta | 2.2546 | ||
| 3-Year Sharpe Ratio | -0.65 | ||
| 3-Year Sortino Ratio | -1.06 | ||
| Volatility % | 85.26 | ||
| 14-Day RSI | 50.41 | ||
| 14-Day ATR (₹) | 1.064077 | ||
| 20-Day SMA (₹) | 23.6615 | ||
| 12-1 Month Momentum % | -53.36 | ||
| 52-Week Range (₹) | 15.2 - 52.5 | ||
| Shares Outstanding (Mil) | 55.21 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Balaxi Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Balaxi Pharmaceuticals Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| 5:1 Stock Split | 2024-05-30 | 136.71 (-4.40%) |
Show
Entries
Balaxi Pharmaceuticals Ltd Frequently Asked Questions
What is Balaxi Pharmaceuticals Ltd(NSE:BALAXI)'s stock price today?
The current price of NSE:BALAXI is ₹24.04. The 52 week high of NSE:BALAXI is ₹52.50 and 52 week low is ₹15.20.
When is next earnings date of Balaxi Pharmaceuticals Ltd(NSE:BALAXI)?
The next earnings date of Balaxi Pharmaceuticals Ltd(NSE:BALAXI) is .
Does Balaxi Pharmaceuticals Ltd(NSE:BALAXI) pay dividends? If so, how much?
Balaxi Pharmaceuticals Ltd(NSE:BALAXI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Balaxi Pharmaceuticals Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers